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Cancer Therapy Network
Summary
Background The necessary margin of excision for cutaneous melanomas greater than 2 mm in thickness is 
controversial. At a median follow-up of 5 years, ﬁ ndings from our previously published randomised trial of narrow 
(1 cm) versus wide (3 cm) excision margins in patients with thick cutaneous melanomas showed that narrow margins 
were associated with an increased frequency of locoregional relapse, but no signiﬁ cant diﬀ erence in overall survival 
was apparent. We now report a long-term survival analysis of that trial.
Methods We did a randomised, open-label multicentre trial in 59 hospitals—57 in the UK, one in Poland, and one in 
South Africa. Patients with one primary localised cutaneous melanoma greater than 2 mm in Breslow thickness on 
the trunk or limbs (excluding palms or soles) were randomly assigned (1:1) centrally to receive surgery with either a 
1 cm or 3 cm excision margin following an initial surgery. The randomisation lists were generated with random 
permuted blocks and stratiﬁ ed by centre and extent of initial surgery. The endpoints of this analysis were overall 
survival and melanoma-speciﬁ c survival. Analyses were done in the intention-to-treat population. This trial was not 
registered because it predated mandatory trial registration.
Findings Between Dec 16, 1992, and May 22, 2001, we randomly assigned 900 patients to surgery with either a 1 cm 
excision margin (n=453) or a 3 cm excision margin (n=447). At a median follow-up of 8·8 years (106 months 
[IQR 76–135], 494 patients had died, with 359 of these deaths attributed to melanoma. 194 deaths were attributed to 
melanoma in the 1 cm group compared with 165 in the 3 cm group (unadjusted hazard ratio [HR] 1·24 [95% CI 
1·01–1·53]; p=0·041). Although a higher number of deaths overall occurred in the 1 cm group compared with the 
3 cm group (253 vs 241), the diﬀ erence was not signiﬁ cant (unadjusted HR 1·14 [95% CI 0·96–1·36]; p=0·14). 
Surgical complications were reported in 35 (8%) patients in the 1 cm excision margin group and 65 (15%) patients in 
the 3 cm group.
Interpretation Our ﬁ ndings suggest that a 1 cm excision margin is inadequate for cutaneous melanoma with Breslow 
thickness greater than 2 mm on the trunk and limbs. Current guidelines advise a 2 cm margin for melanomas greater 
than 2 mm in thickness but only a 1 cm margin for thinner melanomas. The adequacy of a 1 cm margin for thinner 
melanomas with poor prognostic features should be addressed in future randomised studies.
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Introduction
The risk of metastatic spread from a malignant 
melanoma is estimated on the basis of histopathological 
features such as the Breslow thickness, mitotic rate, and 
the presence of microscopic ulceration.1,2 Whether the 
surgical margins that are taken around the primary 
tumour aﬀ ect metastatic spread is unclear, despite 
having been the subject of several randomised clinical 
trials.3–7 Historically, wide surgical margins of 5 cm or 
more were taken around primary melanomas in an 
attempt to not only excise the primary tumour but also 
to encompass local micrometastatic disease in the 
vicinity of the tumour.8,9 In ﬁ ndings from all previously 
reported randomised trials comparing wide (3–5 cm) 
with narrow (1–2 cm) margins, no signiﬁ cant diﬀ erence 
in overall survival between the groups has been reported. 
For melanoma-speciﬁ c survival, although no trial has 
shown a signiﬁ cant diﬀ erential risk associated with 
diﬀ erent surgical margin widths, ﬁ ndings from 
two trials3,4 and the previous report of this trial10 suggest 
a possible detrimental eﬀ ect of narrow margins on 
melanoma-speciﬁ c survival. In a Swedish Melanoma 
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Study Group trial3 of patients randomly assigned to 
excision margins of either 2 cm or 5 cm for trunk and 
extremity melanomas with a Breslow thickness 
0·8–2·0 mm (median 1·2 mm), the hazard ratio (HR) 
for melanoma deaths for narrow margins compared 
with wide margins was 1·22 (95% CI 0·88–1·69; p=0·24) 
with a median follow-up of 11 years. Additionally, the 
Intergroup Melanoma Surgical Trial4 of patients 
randomly assigned to either a 2 cm or 4 cm excision 
margin for trunk and extremity melanomas with 
Breslow thickness 1–4 mm (median 1·96 mm) showed a 
non-signiﬁ cant diﬀ erence (p=0·07) in 10-year disease-
speciﬁ c survival between groups (70% for the 2 cm 
group and 77% for the 4 cm group). However, ﬁ ndings 
from a second Swedish Melanoma Study Group trial6 
that randomly assigned patients with melanomas of 
Breslow thickness greater than 2 mm (median 3·1 mm) 
to either a 2 cm or a 4 cm excision margin showed no 
diﬀ erence in melanoma-speciﬁ c survival between the 
two groups (HR 0·99 [95% CI 0·78–1·26]; p=0·95).
In 2004, we reported the ﬁ ndings from our randomised 
clinical trial10 of patients with high-risk malignant 
melanoma (Breslow thickness ≥2 mm) randomly 
assigned to excision margins of either 1 cm or 3 cm, with 
a median follow-up of 5 years. We showed a negative 
association between narrow margins and locoregional 
relapse-free survival (deﬁ ned as local recurrence, 
in-transit metastases, and regional lymph node 
metastases); ie, a 1 cm margin was associated with a 
signiﬁ cantly greater risk of locoregional recurrence than 
the 3 cm margin (multivariable adjusted HR 1·34 
[95% CI 1·06–1·71]; p=0·02). No signiﬁ cant diﬀ erences 
Research in context
Evidence before this study
We searched PubMed for articles published up to Aug 1, 2015, 
on randomised trials assessing surgical excision margins in 
cutaneous melanoma, using the search terms “melanoma”, 
“margins”, “excision”, and “surgery”. No languages were 
excluded from the search. We identiﬁ ed ﬁ ve randomised trials 
that analysed the eﬀ ect of surgical margins on outcomes in 
cutaneous melanoma. None of these trials have shown a 
signiﬁ cant eﬀ ect of the choice of surgical margins on either 
locoregional relapse or melanoma-speciﬁ c survival. 
However, some of these studies have shown non-signiﬁ cant 
results favouring wider margins in minimising locoregional 
and distant relapse.
Added value of this study
This study reports on long-term survival analysis and, to our 
knowledge, is the ﬁ rst to show that wider surgical margins result 
in a signiﬁ cant improvement in melanoma-speciﬁ c survival.
Implications of all the available evidence
This study, alongside the other randomised trials, reiterates 
current international guidelines stating that a 1 cm margin is 
inadequate for the treatment of a melanoma greater than 2 mm 
in Breslow thickness. It lends support to further investigation of 
the adequacy of a 1 cm margin for melanomas between 1 mm 
and 2 mm in thickness, especially those with other poor 
prognostic features, for which most international guidelines at 
present still advise a 1 cm excision. 
Figure 1: Trial proﬁ le
*Initial excision by the proposed pathway. †Initial excision by the alternative pathway.
372 assigned to 1 cm margin 
742 received 1 mm margin initial
excision* and randomised
453 assigned to 1 cm margin
442 received assigned treatment
453 included in long-term
intention-to-treat analysis
2 lost to follow-up
253 died
370 assigned to 3 cm margin 
900 patients enrolled
81 assigned to 1 cm margin
(ie, no further excision)
77 assigned to 3 cm margin
(ie, 2 cm further excision)
447 assigned to 3 cm margin
436 received assigned treatment
447 included in long-term
intention-to-treat analysis
2 lost to follow-up
241 died
158 received 1 cm margin initial
excision† and randomised
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were apparent between the two groups for either 
melanoma-speciﬁ c survival or overall survival. We now 
report an extended follow-up of the survival endpoints of 
this trial with a median follow-up of 8·8 years.
Methods
Study design and participants
We have previously described the study design, patient 
eligibility criteria, trial protocol, and endpoints of the 
randomised trial in detail.10 Brieﬂ y, between Dec 16, 1992, 
and May 22, 2001, we did a randomised, open-label 
multicentre trial in 59 centres in the UK, South Africa, 
and Poland. The trial was done under the auspices of 
the UK Melanoma Study Group, the British Association 
of Plastic Surgeons, and the Scottish Cancer Therapy 
Network and was approved by the local ethics 
committees of all participating centres. Patients aged 
18 years or older with one primary localised cutaneous 
melanoma greater than 2 mm in Breslow thickness 
arising on the trunk or limbs (but not including the 
soles of feet or palms of hands) were eligible for the 
study. Before randomisation, the primary melanoma 
was excised in an initial surgery with either a 1 mm 
(proposed pathway) or 1 cm (alternative pathway) 
margin of excision. A diagnosis of melanoma with a 
Breslow thickness greater than 2 mm was conﬁ rmed 
histopathologically by histopathologists in participating 
centres. Two histopathologists from the trial 
management group did a histopathological review of 
the primary melanoma in all cases. Patients could not 
have any previous history of cancer, other than basal cell 
carcinoma. Written informed consent was obtained for 
all participants. This trial was not registered as it 
predated mandatory trial registration.
Randomisation and masking
We randomly assigned patients (1:1) to either a 1 cm 
surgical excision or a 3 cm surgical excision as the 
measured clinical margin taken around the primary 
melanoma lesion. We did the randomisation centrally 
by telephone call from the patient’s treating centre to 
The Institute of Cancer Research Clinical Trials and 
Statistics Unit (ICR-CTSU). Randomisation lists were 
generated at the ICR-CTSU with random permuted 
blocks and stratiﬁ ed according to centre and extent of 
initial surgery. Treatment allocation was not masked.
Procedures
Patients who had a 1 mm initial excision (proposed 
pathway) received either a further 1 cm or 3 cm excision. 
Patients who had a 1 cm initial excision (alternative 
pathway) received either no further treatment or a further 
2 cm excision. If further surgery was needed after the 
initial excision, it had to be done within 45 days. 
The method of surgical closure was at the discretion of 
the participating surgeon. Elective lymph node dissection 
and sentinel node biopsy were not part of routine practice 
at the time the trial was undertaken and adjuvant 
chemotherapy was not allowed in the trial protocol. After 
treatment, patients were followed up for local and distant 
relapse and death every 3 months for the ﬁ rst 2 years, 
then every 6 months for up to 5 years, and annually 
thereafter. Assessment of disease at the point of relapse 
was by standard clinical practice within participating 
centres at that time. Data from trial case report forms 
(when available) were used to identify cause of death. 
To maximise the amount of survival data obtained, we 
also traced UK patients (n=790) for their vital status and 
in January, 2012, we requested the death certiﬁ cates of 
patients known to have died to identify the cause of death 
as stated on the certiﬁ cate. Death certiﬁ cates were not 
obtained for non-UK patients (n=110). Death was classed 
as melanoma-speciﬁ c if the cause of death was reported 
as melanoma on the clinical trial case-report form for 
1 cm excision 
margin (n=453)
3 cm excision 
margin (n=447)
Sex
Male 248 (55%) 220 (49%)
Female 205 (45%) 227 (51%)
Age (years)
<60 243 (54%) 236 (53%)
≥60 210 (46%) 211 (47%)
Median 58·7 (47·1–68·8) 58·7 (47·3–70·1)
Tumour thickness (mm)
<2·50 133 (29%) 114 (26%)
2·50–3·49 136 (30%) 144 (32%)
3·50–4·49 77 (17%) 77 (17%)
4·50–5·49 40 (9%) 40 (9%)
≥5·50 65 (14%) 72 (16%)
Missing information 2 (<1%) 0
Median 3 (2·3–4·2) 3·1 (2·4–4·5)
Tumour thickness (mm)*
≤1·00 0 2 (<1%)
1·01–2·00 55 (12%) 44 (10%)
2·01–4·00 280 (62%) 275 (62%)
>4·00 116 (26%) 126 (28%)
Missing information 2 (<1%) 0
Site
Distal 136 (30%) 140 (31%)
Proximal 108 (24%) 97 (22%)
Trunk 203 (45%) 206 (46%)
Missing information 6 (1%) 4 (<1%)
Ulceration (>1 mm)
Absent 249 (55%) 233 (52%)
Present 144 (32%) 154 (35%)
Not assessed 60 (13%) 60 (13%)
Initial surgery
Proposed (1 mm) 372 (82%) 370 (83%)
Alternative (1 cm) 81 (18%) 77 (17%)
Data are n (%) or median (IQR). *UICC classiﬁ cation. 
Table 1: Baseline characteristics of the intention-to-treat population
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death, or if any evidence was present of distant metastatic 
melanoma at the time of death (as reported in patient 
ﬁ les or on death certiﬁ cates). Attribution of the cause of 
death as stated on the death certiﬁ cate was masked to 
clinical records and treatment group.
Outcomes
The primary endpoints of the original trial10 were 
locoregional recurrence and disease-free survival. Because 
of our restricted ability to obtain recurrence data in later 
years, these endpoints were not reassessed in the present 
long-term analysis. Instead, we assessed the original 
secondary endpoints of overall survival, measured as time 
from randomisation to death from any cause, and 
melanoma-speciﬁ c survival, measured as time from 
randomisation to death reported to be from melanoma. 
Data for surgical complications were obtained as part of 
the original analysis. 
Statistical analysis
The original planned sample size was 600 patients, 
based on an expected 3-year local or in-transit recurrence 
rate of 15%; however, because of a lower recurrence rate 
than expected, the sample size was increased to 900 after 
discussion with the trial management group and the 
data monitoring committee.10 At the time of writing the 
protocol, we expected that 40–50% of patients with a 
3 cm excision would have disease recurrence within 
2–3 years. At the time patients were recruited, survival 
after diagnosis of metastatic relapse was understood to 
be poor. The protocol did not specify a sample size for 
the secondary survival endpoints. Unless otherwise 
stated, we did all analyses in the intention-to-treat 
population, which includes all randomly assigned 
patients. For overall survival, patients not known to have 
died were censored at the date of last follow-up. 
For melanoma-speciﬁ c survival, patients who died of 
non-melanoma causes were censored at the time of 
death and patients who died from an unknown cause 
were censored on the day before their date of death. Both 
UK and non-UK patients who were not known to have 
died were censored at the date of their last visit. To assess 
the robustness of these assumptions we did a competing-
risks analysis, treating conﬁ rmed non-melanoma deaths 
as the competing event.
We constructed Kaplan-Meier curves11 and calculated 
HRs using the Cox proportional hazards model;12 we 
compared treatment groups using the log-rank test. 
We calculated absolute risk diﬀ erence at 10 years with 
normal estimated 95% CIs and assessed the eﬀ ect of 
individual prognostic factors in a multivariable analysis 
using the same Cox proportional hazards model as in our 
previous report,10 adjusting for age. Variables are included 
in the model as categorical indicators, other than 
tumour thickness which was classiﬁ ed as 0–2·49 mm, 
2·50–3·49 mm, 3·50–4·49 mm, 4·50–5·49 mm, and 
5·50 mm or more, and ﬁ tted as a linear eﬀ ect. HRs 
(with 95% CIs) are presented, with HRs greater than 1 
suggesting a disadvantage to the 1 cm margin group 
relative to the 3 cm margin group. We tested the 
proportionality assumption of the Cox model with 
Schoenfeld residuals. For the competing risks analysis, 
we plotted cumulative incidence functions for each cause 
of death (melanoma and non-melanoma) and compared 
treatment groups with Gray’s test. HRs were obtained 
from the univariate Fine and Gray model.13,14 We also did 
a multivariable analysis with the Fine and Gray model, 
including the same variables as the multivariable Cox 
model. To explore the eﬀ ect of age on cause of death, 
patients were classiﬁ ed at randomisation in ﬁ ve age 
groups containing about equal numbers of patients 
(<45 years, 45–53 years, 54–63 years, 64–70 years, and 
≥71 years), deﬁ ned using quintiles and rounding to the 
nearest whole number. We estimated the rates of death 
from melanoma and other causes for each age group as 
Figure 2: Overall survival (A) and melanoma-speciﬁ c survival (B)
HR=hazard ratio.
100
75
50
25
0
Ov
er
al
l s
ur
vi
va
l (
%
)
0 2 4 6 8 10 12
12
Number at risk
(events)
1 cm margin
3 cm margin
453 (76)
447 (62)
371 (61)
381 (63)
292 (49)
302 (35)
198 (28)
222 (24)
123 (14)
143 (25)
66 (10)
72 (9)
23 (5)
33 (9)
1 cm margin
3 cm margin
HR 1·14 (95% CI 0·96–1·36); log-rank p=0·14
A
100
75
50
25
0
M
el
an
om
a-
sp
ec
iﬁ
c s
ur
vi
va
l (
%
)
0 2 4 6 8 10
Follow-up (years)
Number at risk
(events)
1 cm margin
3 cm margin
453 (66)
447 (55)
371 (59)
381 (51)
292 (42)
302 (24)
198 (17)
222 (12)
123 (4)
143 (12)
66 (3)
72 (3)
23 (2)
33 (3)
HR 1·24 (95% CI 1·01–1·53); log-rank p=0·041
B
Articles
188 www.thelancet.com/oncology   Vol 17   February 2016
the probability of dying from a speciﬁ c cause in 2-year 
intervals from randomisation if the patient was alive at 
the beginning of each 2-year interval, using cumulative 
incidence functions from the competing risks analysis.
Because we obtained death certiﬁ cates for UK patients 
only, we did a sensitivity analysis including UK patients 
only. For this analysis we constructed Kaplan-Meier 
curves and calculated HRs using the Cox proportional 
hazards model for UK patients only.
We did a post-hoc subgroup analysis to assess whether 
sex, tumour thickness, age group, site, ulceration, and 
proposed versus alternative pathway initial excision were 
associated with treatment eﬀ ect. We used Wald tests to 
compare the HRs between subgroups. To compensate 
for multiplicity for subgroup analyses, p values of less 
than 0·01 were deemed signiﬁ cant, therefore these HRs 
are presented with corresponding 99% CIs. We used 
two-sided signiﬁ cance tests throughout.
This was the ﬁ rst and only analysis that had been done 
on this dataset since the initial report of this trial. We did 
the competing risks analysis with R 3.0.2 and all other 
analyses with Stata version 11.2.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Dec 16, 1992, and May 22, 2001, 900 patients 
were enrolled at 57 hospitals in the UK, one hospital in 
Poland, and one hospital in South Africa (appendix) and 
received an initial excision of 1 mm or 1 cm, and were 
then randomly allocated to either a total 1 cm surgical 
margin (n=453) or a total 3 cm surgical margin (n=447; 
ﬁ gure 1). 442 (98%) patients in the 1 cm group 
and 436 (98%) patients in the 3 cm group underwent 
the allocated treatment. Baseline characteristics were 
well balanced between the two groups (table 1). 
Median follow-up for all patients was 5·7 years 
(68 months [IQR 35–103]) and median follow-up in 
patients not known to have died (censoring at death) was 
8·8 years (106 months [76–135]). Median follow-up for 
the UK patients for whom a death certiﬁ cate analysis was 
done (censoring at death) was 9·3 years (111 months 
[IQR 82–141]) and median follow-up in non-UK patients 
was 6·3 years (76 months [62–100]). 494 deaths were 
reported; 359 of these were death from melanoma. 
For three participants (two in the 1 cm margin group, one 
in the 3 cm group), melanoma was present at the time of 
death but this was not the cause of death. Cause of death 
was unknown for ten patients (three in the 1 cm margin 
group, seven in the 3 cm group). Four patients did not 
have any follow-up after randomisation and were 
censored at randomisation.
The snapshot used for the current analysis was taken 
on Aug 31, 2012, after information from the death 
certiﬁ cate analysis had been obtained. 253 deaths 
occurred overall in 453 patients in the 1 cm margin 
group and 241 occurred in 447 patients in the 3 cm group 
(unadjusted HR 1·14 [95% CI 0·96–1·36]; p=0·14; 
ﬁ gure 2). 194 deaths attributed to melanoma occurred in 
the 1 cm margin group compared with 165 in the 3 cm 
margin group (unadjusted HR 1·24 [95% CI 1·01–1·53]; 
p=0·041; ﬁ gure 2). The estimated absolute diﬀ erence in 
melanoma-speciﬁ c survival at 10 years between the 
two groups was 5·95% (95% CI –0·54 to 12·44). 
The proportionality assumption of the Cox model was 
not violated (appendix). Results from the sensitivity 
analysis of UK patients only (n=338 in the 1 cm margin 
group; n=392 in the 3 cm margin group) showed HRs of 
1·11 (95% CI 0·92–1·33) for overall survival and 1·21 
(0·97–1·50) for melanoma-speciﬁ c survival; the results 
were consistent with the primary result.
773 patients (385 in the 1 cm group and 388 in the 3 cm 
group) had complete data for all known prognostic 
factors and were included in a multivariable analysis 
(table 2). Having adjusted for known prognostic factors, 
the eﬀ ect of a 1 cm margin versus a 3 cm margin was 
similar to that found in the unadjusted analysis. When 
we assessed interactions between margin width and sex, 
See Online for appendix
n (%) Overall survival Melanoma-speciﬁ c survival
Excision margin
3 cm 388 (50%) 1·00* 1·00*
1 cm 385 (50%) 1·19 (0·99–1·45) 1·28 (1·02–1·61)
p value ·· 0·070 0·031
Sex
Female 354 (46%) 1·00* 1·00*
Male 419 (54%) 1·38 (1·11–1·71) 1·38 (1·07–1·77)
p value ·· 0·0035 0·013
Tumour thickness† (mm) 773 (100%) 1·18 (1·10–1·27) 1·23 (1·13–1·33)
p value ·· <0·0001 <0·0001
Ulceration
Absent 477 (62%) 1·00* 1·00*
Present 296 (38%) 1·68 (1·38–2·04) 1·74 (1·39–2·19)
p value ·· <0·0001 <0·0001
Site
Distal limb 244 (32%) 1·00* 1·00*
Proximal limb 174 (23%) 1·23 (0·93–1·63) 1·46 (1·04–2·05)
Trunk 355 (46%) 1·41 (1·09–1·81) 1·71 (1·26–2·31)
p value ·· 0·029 0·0026
Age (years)
<60 400 (52%) 1·00* 1·00*
≥60 373 (48%) 1·49 (1·23–1·81) 1·12 (0·89–1·39)
p value ·· 0·0001 0·34
Data are n (%), hazard ratio (95% CI) of 773 patients with available data. p values from Wald test. *Reference group. 
†Tumour thicknesses classiﬁ ed as 0·00–2·49 mm, 2·50–3·49 mm, 3·50–4·49 mm, 4·50–5·49 mm, and ≥5·50 mm, and 
ﬁ tted as linear eﬀ ects. 
Table 2: Multivariable analysis of prognostic factors in overall survival and melanoma-speciﬁ c survival 
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tumour thickness, age group, site, and ulceration in a 
subgroup analysis, none were signiﬁ cant for either 
overall survival or melanoma-speciﬁ c survival (ﬁ gure 3). 
When the eﬀ ect of competing deaths due to other 
causes was taken in account, the cumulative incidence of 
death from melanoma was higher in the 1 cm margin 
Figure 3: Univariable subgroup analyses of overall survival (A) and melanoma-speciﬁ c survival (B)
The dotted line shows the hazard ratio for all patients. Data excludes patients with unknown values for each variable. TBT=total Breslow thickness. *95% CIs 
presented for all patients; 99% CIs presented for subgroups. 
Events (n)
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group than in the 3 cm margin group (ﬁ gure 4; point 
estimates of cumulative incidence at 8·8 years were 
47·9% [95% CI 42·8–53·2] in the 1 cm margin group, 
38·1% [33·3–43·4] in the 3 cm group). The multivariable 
analysis done with Fine and Gray’s model for melanoma-
speciﬁ c deaths showed similar results to the Cox model 
for melanoma-speciﬁ c survival (appendix). No diﬀ erences 
between the two margin widths were noted regarding the 
cumulative incidence of death due to other causes 
(ﬁ gure 4; point estimates of cumulative incidence at 
8·8 years were 14·5% [95% CI 10·1–20·6] in the 1 cm 
margin group, 18·2% [13·6–24·0] in the 3 cm group). 
The association of prognostic factors with non-melanoma 
death was assessed; only age was found to be associated 
(appendix). Deaths from melanoma and non-melanoma 
causes over time in all age groups are shown in table 3. 
The number of non-melanoma deaths in younger age 
groups was negligible, but became more predominant in 
later years of follow-up for older patients (table 3). Surgical 
complications were reported in 35 (8%) of 453 patients in 
the 1 cm group and 65 (15%) of 447 patients in the 3 cm 
group. The most common complications were partial or 
complete graft loss (ten [2%] in the 1 cm group, 20 [4%] in 
the 3 cm group) and wound dehiscence (seven [2%] in the 
1 cm group, nine [2%] in the 3 cm group).
Discussion
At a median follow-up of 8·8 years (106 months) the risk 
of death from melanoma was signiﬁ cantly higher in the 
narrow (1 cm) margin group than in the wider (3 cm) 
margin group. The poorer prognosis from melanoma 
associated with the 1 cm margin of excision was not 
speciﬁ c to any particular subgroup of patients. 
The estimated risk of death from any cause was higher 
in the 1 cm margin group than in the 3 cm margin 
group, although this diﬀ erence was not signiﬁ cant. 
A limitation of our study is that complete data were not 
available for all patients; in particular, death certiﬁ cates 
were not obtained for non-UK patients. However, the 
results of a sensitivity analysis of UK patients only were 
consistent with the primary results.
Findings from our previous report of this trial10 with a 
median follow-up of 5 years showed that, in patients with 
high-risk melanoma, a 1 cm excision margin was associated 
with a signiﬁ cant increase in locoregional relapse compared 
with a 3 cm excision margin. In that report, although the 
number of deaths diﬀ ered between the two study groups, 
the diﬀ erence was not signiﬁ cant (128 deaths from 
melanoma in the group with 1 cm excision margins 
compared with 105 in the group with 3 cm excision 
margins; HR 1·24 [95% CI 0·96–1·61], p=0·1). Additionally, 
no diﬀ erences were noted in overall survival between the 
two groups (32·2% in the 1 cm group vs 30·9% in the 3 cm 
group; HR 1·07 [95% CI 0·75–1·36], p=0·6).
The current analysis does not include an updated 
analysis of the locoregional recurrence endpoint because 
follow-up data for locoregional relapse beyond 5 years are 
sparse. This report describes analyses only of melanoma-
speciﬁ c survival and overall survival, and shows that a 
narrow margin signiﬁ cantly reduced melanoma-speciﬁ c 
survival compared with a wider margin. Locoregional 
relapse is the most common ﬁ rst site of relapse of 
metastatic melanoma and, accordingly, an increased risk 
of locoregional relapse in the narrow margin group might 
suggest an increased future risk of melanoma-speciﬁ c 
death. During the period of this study, when no eﬀ ective 
systemic therapies for metastatic melanoma were available, 
stage IV disease was associated with a very poor prognosis 
with a median survival of between 8 and 18 months 
depending on the pattern of metastatic spread.15 Although 
age, sex, tumour thickness, ulceration, and tumour site all 
seem to be prognostic factors for overall survival, only age 
was shown to aﬀ ect non-melanoma deaths, which occurred 
in similar numbers in the 1 cm and the 3 cm groups.
Figure 4: Cumulative incidence for death due to melanoma (A) and death due to other causes (B)
HR=hazard ratio.
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Because sentinel node biopsy was not done routinely 
in this trial,10 the trial groups might have been 
imbalanced in terms of clinically occult disease within 
regional lymph nodes at the time of randomisation, 
which could have biased the outcome of the trial. 
Also the prognostic importance of mitotic rate, 
lymphovascular invasion, and microsatellitosis was 
not known when this study was initiated. However, 
treatment allocation was by randomisation, which aims 
to ensure no systematic diﬀ erences exist between the 
two groups for both known and unknown prognostic 
factors. Any imbalances in unobserved factors in this 
study would be due to chance and a chance imbalance in 
a study of this size is unlikely to aﬀ ect the outcomes. 
Because the trial groups were well balanced in terms of 
other known prognostic factors for outcome at the time 
of trial recruitment (eg, sex, tumour thickness, disease 
site) and ulceration was slightly more prevalent in the 
3 cm group, the sentinel node status is unlikely to be 
worse in the 1 cm group than in the 3 cm group, although 
a chance imbalance remains possible.
This study cannot establish whether locoregional relapse 
predisposes patients to the subsequent development of 
distant metastatic disease, or whether the development of 
locoregional disease is merely correlated with and predates 
the development of metastatic disease. However, a 1 cm 
clinical margin should be adequate to completely excise a 
primary melanoma with negative microscopic margins. 
Because a 3 cm margin resulted in a decreased number of 
melanoma deaths, this would suggest that surgically 
intervening in a micrometastatic process in the 3 cm 
around the primary tumour can somehow aﬀ ect the later 
metastatic process at more distant sites. Previous studies 
have shown a signiﬁ cant increase in local recurrence rates 
after 1 cm excisions,6,16 suggesting that 1 cm margins 
might not be adequate to deal with local microsatellitosis.
Previous randomised studies of elective17–21 or selective22 
lymph node dissection have not shown a signiﬁ cant 
diﬀ erence in melanoma-speciﬁ c survival. The absence 
of a proven survival beneﬁ t in these nodal studies is at 
odds with the probable biological hypothesis for an eﬀ ect 
on survival shown in this study—ie, that removal of 
microsatellites around the primary tumour aﬀ ects the 
development of metastatic disease. However, because 
subgroup analyses in these studies raised the possibility 
of survival beneﬁ t for prophylactic lymph node clearance 
that was not detected at the point of randomisation,22 
there might be a consistent biological process underlying 
the eﬀ ect noted in this study and in previous studies of 
prophylactic lymph node clearance.
Current international guidelines advise a 2 cm excision 
for melanomas greater than 2 mm in thickness and 
ﬁ ndings from the other major randomised study for thick 
melanomas6 suggested that a 4 cm excision was not better 
than a 2 cm excision in terms of melanoma-speciﬁ c 
survival. Hence, although the ﬁ ndings from our study 
suggest that a 1 cm margin seems inadequate for excision 
of melanomas thicker than 2 mm, margins greater than 
2 cm need not necessarily be taken. Our study has 
re-emphasised that the choice of surgical margins taken 
around a cutaneous melanoma is important and, to our 
knowledge, for the ﬁ rst time provides evidence to suggest 
that a narrower excision margin used for thick primary 
tumours aﬀ ects melanoma-speciﬁ c survival. This ﬁ nding 
might be pertinent for speciﬁ c melanomas for which 
narrow (1 cm) margins are presently advised—ie, 
melanomas between 1 mm and 2 mm in thickness with 
other adverse prognostic features (ulceration or high 
mitotic rate, or both). The possible diﬀ erence between a 
1 cm and 2 cm margin for melanomas greater than 1 mm 
in thickness is being investigated in a randomised trial in 
progress (NCT02385214). 
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<45 years 
(n=180)
45–53 years 
(n=185)
54–63 years 
(n=190)
64–70 years 
(n=161)
≥71 years 
(n=184)
Patients alive at 2 years 159 (88%) 157 (85%) 155 (82%) 143 (89%) 138 (75%)
Total deaths ≤2 years 18 27 30 15 46
Deaths from melanoma 17 (11%) 27 (17%) 27 (17%) 14 (10%) 36 (26%)
Deaths from other cause(s) 1 (<1%) 0 3 (2%) 1 (<1%) 10 (7%)
Patients alive at 4 years 121 (67%) 129 (70%) 127 (67%) 112 (70%) 105 (57%)
Total deaths from 
2·01–4·00 years
29 22 17 24 32
Deaths from melanoma 29 (23%) 21 (16%) 17 (13%) 22 (19%) 21 (20%)
Deaths from other cause(s) 0 1 (<1%) 0 2 (2%) 11 (11%)
Patients alive at 6 years 80 (44%) 90 (49%) 93 (49%) 76 (47%) 81 (44%)
Total deaths from 
4·01–6·00 years
13 13 16 21 20
Deaths from melanoma 13 (14%) 12 (11%) 13 (13%) 16 (20%) 12 (15%)
Deaths from other cause(s) 0 1 (1%) 3 (3%) 5 (6%) 8 (10%)
Patients alive at 8 years 49 (27%) 60 (32%) 56 (29%) 47 (29%) 54 (29%)
Total deaths from 
6·01–8·00 years
5 4 12 14 16
Deaths from melanoma 4 (7%) 2 (3%) 7 (11%) 10 (19%) 6 (10%)
Deaths from other cause(s) 1 (2%) 2 (3%) 5 (7%) 4 (7%) 10 (17%)
Patients alive at 10 years 30 (17%) 29 (16%) 30 (16%) 26 (16%) 23 (13%)
Total deaths from 
8·01–10·00 years
5 5 1 5 21
Deaths from melanoma 5 (14%) 3 (7%) 0 1 (3%) 7 (24%)
Deaths from other cause(s) 0 2 (4%) 1 (3%) 4 (12%) 14 (50%)
Patients alive at 12 years 8 (4%) 11 (6%) 15 (8%) 9 (6%) 13 (7%)
Total deaths from 
10·01–12·00 years
2 1 4 5 6
Deaths from melanoma 2 (13%) 1 (5%) 1 (4%) 1 (6%) 1 (6%)
Deaths from other cause(s) 0 0 3 (16%) 4 (34%) 5 (32%)
Data at 2-year intervals from randomisation. Cutoﬀ  points for age were selected using quintiles rounded to the nearest 
whole number. Deaths presented as n or n (%).
 Table 3: Deaths from melanoma and other causes in diﬀ erent age groups
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